Living Through the Fentanyl Era: A Harm Reduction Primer
Naloxone, test strips, xylazine, and what meets people where they are without judgment.
Body: [Draft covers: what fentanyl is and isn’t, why supply contamination is the defining risk factor, naloxone step-by-step (including multi-dose scenarios with high-potency synthetics), fentanyl test strip limitations (won’t detect nitazenes), xylazine and what’s different about it, Good Samaritan laws state-by-state, and the cultural shift from abstinence-only to harm reduction. Explicitly non-judgmental; assumes readers include people in active use.]
Related: Xylazine, explained | Nitazenes Watch | How to use naloxone, step by step | Arizona’s Good Samaritan law.
Sources Cited
- 01.Ahttps://www.cdc.gov/stopoverdoseCDC Stop Overdose
- 02.A
Filed Under
NaloxoneFentanyl Test StripsOverdose
Continue reading
More from this section
69,973 Deaths. The Number That Proves Harm Reduction Works—and the Policy Quietly Undoing It.
CDC provisional data projects 69,973 overdose deaths for 2025—a 13.9% decline. The same spring, SAMHSA ended federal funding for fentanyl test strips. The drug supply has never been more dangerous.
Harm ReductionResponding to the Emerging Threat of Xylazine
On April 24, SAMHSA banned federal funding for fentanyl, xylazine, and medetomidine test strips for public distribution — precisely as the June 2026 Labcorp report shows medetomidine in 91% of Philadelphia's fentanyl supply. The policy contradiction that kills people who use drugs.
Harm ReductionThe Drug Inside the Drug: How Medetomidine Is Breaking Every Overdose Response Playbook
Medetomidine, a veterinary sedative 200 times more potent than xylazine, has displaced xylazine in Philadelphia's fentanyl supply and is confirmed in nine states. It produces sedation that naloxone cannot reverse, withdrawal that requires ICU-level care in 91% of hospitalized patients, and clinical presentations that emergency departments are consistently misidentifying.